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Abstract
Background: Current guidelines encourage the use of statins to reduce the risk of cardiovascular disease in diabetic
patients; however the impact of these drugs on diabetic retinopathy is not well defined. Moreover, pleiotropic effects of
statins on the highly specialised retinal microvascular endothelium remain largely unknown. The objective of this study was
to investigate the effects of clinically relevant concentrations of simvastatin on retinal endothelium in vitro and in vivo.
Methods and Findings: Retinal microvascular endothelial cells (RMECs) were treated with 0.01–10 mM simvastatin and a
biphasic dose-related response was observed. Low concentrations enhanced microvascular repair with 0.1 mM simvastatin
significantly increasing proliferation (p,0.05), and 0.01 mM simvastatin significantly promoting migration (p,0.05),
sprouting (p,0.001), and tubulogenesis (p,0.001). High concentration of simvastatin (10 mM) had the opposite effect,
significantly inhibiting proliferation (p,0.01), migration (p,0.01), sprouting (p,0.001), and tubulogenesis (p,0.05).
Furthermore, simvastatin concentrations higher than 1 mM induced cell death. The mouse model of oxygen-induced
retinopathy was used to investigate the possible effects of simvastatin treatment on ischaemic retinopathy. Low dose
simvastatin(0.2 mg/Kg) promoted retinal microvascular repair in response to ischaemia by promoting intra-retinal re-
vascularisation (p,0.01). By contrast, high dose simvastatin(20 mg/Kg) significantly prevented re-vascularisation (p,0.01)
and concomitantly increased pathological neovascularisation (p,0.01). We also demonstrated that the pro-vascular repair
mechanism of simvastatin involves VEGF stimulation, Akt phosphorylation, and nitric oxide production; and the anti-
vascular repair mechanism is driven by marked intracellular cholesterol depletion and related disorganisation of key
intracellular structures.
Conclusions: A beneficial effect of low-dose simvastatin on ischaemic retinopathy is linked to angiogenic repair reducing
ischaemia, thereby preventing pathological neovascularisation. High-dose simvastatin may be harmful by inhibiting
reparative processes and inducing premature death of retinal microvascular endothelium which increases ischaemia-
induced neovascular pathology. Statin dosage should be judiciously monitored in patients who are diabetic or are at risk of
developing other forms of proliferative retinopathy.
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Introduction
Statins are potent and effective inhibitors of cholesterol
biosynthesis that are widely used to treat hypercholesterolemia.
Beyond this well-defined mode of action for statins, several clinical
trials such as 4S [1], WOSCOPS [2], CARE [3], and HPS [4]
have demonstrated that this class of drugs can protect against
cardiovascular disease (CVD) through an additional mechanism
that is independent of cholesterol lowering [5]. Guidelines from
the UK National Institute for Health and Clinical Excellence
(NICE) recommend statin therapy for primary prevention of CVD
in adults who have a 20% or greater 10-year risk [6]. A recent
meta-analysis of 14 randomised trials demonstrated benefits of
statin therapy to reduce vascular mortality in diabetic patients [7].
Consequently, millions of diabetic people are receiving statins [8]
despite the fact that their local effects on certain tissues like the
retina remain largely unknown.
Diabetic retinopathy (DR) is the most common microvascular
complication of diabetes, and it remains a major cause of blindness
and visual disability [9]. The non-proliferative phase of DR is
typified by progressive vasodegeneration [10] leading to inner
retinal ischaemia. As diabetes progresses, reparative function in
the retinal microvasculature is significantly impaired [11] and
ischaemic hypoxia drives up-regulation of angiogenic growth
factors such as vascular endothelial growth factor (VEGF) that
eventually promote a pathologic neovascular response. Retinal
neovascularisation is accompanied by the formation of contractile
scar tissue at the vitreo-retinal interface leading to tractional
retinal detachment or vitreous haemorrhage, both resulting in
severe visual loss. Extensive breakdown of the blood retinal barrier
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2584in response to ischaemia-induced VEGF expression causes
diabetic macular oedema, which is also associated with retinal
vasodegeneration and constitutes another sight-threatening end-
point in DR [12].
Simvastatin is a commonly used drug of its class that has been
shown to improve diabetes-induced coronary endothelial dysfunc-
tion [13]. Similarly, a clinical trial has indicated that simvastatin
may retard the progression of retinopathy in diabetic patients [14]
although a recent case-control study found no association between
statin use and the risk of developing DR [15]. Therefore the
efficacy of statin therapy for DR is ill-defined, and although there
is a potential utility for these drugs to prevent this important
diabetic complication, the precise mechanism of action requires
further investigation.
The actions of statins are pleiotropic and some appear
contradictory. For example, these drugs promote reparative
angiogenesis in murine hind limb ischaemia models [16] but
may also interfere with new blood vessel growth by inhibiting the
geranylgeranylation of RhoA [17]. Furthermore, it has been
shown that statins have a biphasic effect on endothelial cell
migration, promoting the response at low concentrations, and
inhibiting it at high concentrations [18]. The pleiotropic nature of
statin action has been demonstrated on various macro and
microvascular endothelial cells although less attention has been
paid to the highly specialised retinal microvascular endothelium.
This is important because the effects of statins differ according to
the capillary bed [19] and could have an unforeseen biphasic
outcome in the retina, which could be either beneficial or harmful,
especially in the context of DR. This study has investigated the
effects of clinically relevant concentrations of simvastatin on retinal
microvascular endothelial cell function in vitro. Additionally, a pre-
clinical model of ischaemic retinopathy was used to evaluate the
effects of high- and low- dose simvastatin in vivo.
Results
Biphasic Effects of High- and Low- Concentration
Simvastatin on Retinal Microvascular Endothelial Cell
Growth
Retinal microvascular endothelial cells (RMECs) were exposed
to concentrations of simvastatin ranging between 0.1–10 mM.
Cells treated with 0.1 mM simvastatin demonstrated significantly
more population doublings (PD) in 48 hours when compared to
controls (1.9460.06 PD versus 1.6660.04 respectively). This effect
was comparable to that produced by 50 ng/ml VEGF (2.1660.12
PD in the same time frame). By contrast, 10 mM simvastatin fully
suppressed cell proliferation (20.0860.08 PD) (Figure 1A). To
corroborate these findings we used the Bromodeoxyuridine (BrdU)
proliferation assay that identifies replicating cells by their ability to
incorporate BrdU into their DNA during the S phase of the cell
cycle. The percentage of BrdU-positive cells decreased in a dose-
dependent manner (Figure 1C). 0.1 mM simvastatin significantly
increased the number of BrdU-positive cells which was akin to the
VEGF-induced response (Figure 1B) while 5 and 10 mM
simvastatin significantly decreased the number of BrdU-positive
cells (Figure 1B). Further analysis of the cell cycle using the PI
staining method combined with flow cytometry confirmed that the
percentage of RMECs in S phase increased by exposure to 0.1 mM
simvastatin, whereas it decreased when cells were exposed to
10 mM simvastatin (Table 1). Therefore, 0.1 mM simvastatin
increased RMEC proliferation, while 10 mM inhibited it.
To determine if simvastatin of various concentrations modulated
RMEC death, monolayers were exposed to 0.1–20 mM simvastatin
for 24 hours, stained with Propidium Iodide (PI) after ethanol
fixation,and 10000 cellswereassessedbyflowcytometrytoidentify
the sub-G1 peak that represents dead cells (Figure 2A). 10 mM
simvastatin significantly increased the number of dead cells
approximately by two-fold when compared to controls. Significant-
ly, this statin-induced response could be reversed by the addition of
200 mM mevalonate, the end product of 3-hydroxi-3-methyl-
glutaryl-CoA reductase (HMG-CoA reductase) indicating that
inhibition of this enzyme by simvastatin was directly responsible
for induction of cell death. Isoprenoid addition (10 mM Farnesol or
10 mM Geranylgeranyl pyrophosphate) to 10 mM simvastatin also
Figure 1. Dose-Dependent Effect of Simvastatin on RMEC
Proliferation. (A) RMECs were exposed to 0.01–10 mM simvastatin for
48 hours and the population doubling levels (PDLs) were determined
for each treatment-group and compared to controls. *p,0.05,
**p,0.01, ns:not significant, n=4 per group. (B) Immunostaining for
BrdU on RMECs exposed to simvastatin (green) identifies proliferating
cells, all nuclei stained with PI (red). Scale bars 100 mm. (C)
Quantification of BrdU incorporation on RMECs exposed to simvastatin.
*p,0.05, **p,0.01 vs. controls, ns:not significant, n=4 per group.
doi:10.1371/journal.pone.0002584.g001
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TUNEL in situ cell death detection kit was used. RMECs treated
with different concentrations of simvastatin for 24 hours were
stained for TUNEL to label DNA fragmentation in apoptotic cells
(Figure 2B). Consistent with previous results, 10 mM simvastatin
significantly increased the number of TUNEL-positive cells
(Figure 2C). This time a five-fold increase in dead cells was detected
with 10 mM simvastatin compared to controls; the discrepancy in
the results obtained was attributed to the higher sensitivity of the
TUNEL assay to detect cells undergoing apoptosis while the PI-
stained sub-G1 peak identifies only late apoptotic cells. Once more,
mevalonate fully blocked the cell death induced by 10 mM
simvastatin. Consistent with this result was the observation that
prolonged exposure (3 days) of RMECs to 1 mM simvastatin
induced a significant rise in dead cells (data not shown).
Throughout, Dimethyl sulfoxide (DMSO), the initial solvent for
simvastatin, had no effect inducing cell death at the medium
concentration of simvastatin-treated cells. These results demon-
strate that while low concentrations of simvastatin increased retinal
endothelial cell proliferation, high concentrations inhibited cell
proliferation and induced cell death in vitro.
Dual Effects of Simvastatin on Retinal Endothelial Cell
Migration
Pre-confluent RMEC monolayers were treated with 0.01–
10 mM simvastatin. When confluent, a scratch wound was made
and the denuded area imaged and measured at time-0. 12 hours
later the denuded area was again measured and the migratory
activity of the endothelial cells estimated (Figure 3A). 0.01 mM
simvastatin significantly increased RMEC migration in the scratch
wound assay comparable to the effect of 50 ng/ml VEGF. On the
contrary, 10 mM simvastatin significantly decreased RMEC
migration (Figure 3B). 0.1 mM and 1 mM simvastatin had no
significant effect on RMEC migration. Mevalonate addition to the
0.01 mM simvastatin did not reduce cell migration; however N-
omega-nitro-L-arginine methyl ester (L-NAME) addition fully
inhibited the pro-migratory effect of low dose simvastatin,
indicating the involvement of nitric oxide (NO) in RMEC
migration. These data show a hormetic response to simvastatin
on RMEC migration, characterised as low-dose stimulation and
high-dose inhibition.
Simvastatin Differentially Modulates In Vitro Retinal
Microvasculature Angiogenesis
Endothelial cell sprouting and tubulogenesis are basic compo-
nents of the angiogenic process. In order to determine the effects of
high- and low- doses of simvastatin on RMEC sprouting and
tubulogenesis, respective in vitro assays were used. VEGF, as a
positive control, significantly promoted RMEC sprout formation
by 74% when compared to non-treated RMECs. 0.01 mM
simvastatin significantly increased sprout formation by 50%, while
10 mM simvastatin strikingly reduced the number of sprouts per
blob by 67% (Figure 4A). The induction of sprout formation by
0.01 mM simvastatin could be partially reversed by co-incubation
with mevalonate or L-NAME (Figure 4B).
RMECs were cultured on Matrigel extra-cellular matrix to
induce tubule formation. Consistent with previous results,
0.01 mM simvastatin significantly promoted tubule formation by
69% when compared to non-treated RMECs, while 10 mM
simvastatin inhibited tubulogenesis by 37% (Figure 5A). More-
over, most of the RMECs remained round in matrigel when
treated with 10 mM simvastatin (Figure 5B) which suggests an
impaired attachment of RMECs to the extracellular matrix when
exposed to high dose simvastatin. To investigate whether the
simvastatin effect stimulating tubulogenesis was VEGF-dependent,
a humanised monoclonal anti-VEGF antibody fragment, ranibi-
zumab, was added to the in vitro assays containing 0.01 mM
simvastatin. Surprisingly, ranibizumab significantly decreased
both tubule formation and the number of sprouts induced by
the low simvastatin-concentration to control levels (Figure 5C–D)
indicating an important role of VEGF downstream simvastatin.
These results indicate that while low-dose simvastatin promotes
angiogenesis, high doses impair both sprouting and tubulogenesis
of RMECs in vitro. The promoting effect of low-dose simvastatin
on sprouting and tubule formation is mediated via VEGF.
Low-Dose Simvastatin Promoted Vascular Repair in a
Model of Ischemic Retinopathy
To investigate the possible effects of simvastatin treatment on
diabetic retinopathy, the mouse model of oxygen-induced
retinopathy (OIR) was used. Mice eyes subjected to this model
undergo a reproducible vasodegeneration (P7–12), followed by
acute hypoxia (P12–15) leading to aggressive retinal neovascular-
isation (P15–18) which resembles proliferative diabetic retinopa-
thy. Single daily high or low doses of simvastatin were injected
intra-peritoneally from P12 to P17. Flat mounted retinas from P18
mice were assessed for avascular, neovascular, and normovascular
areas (Figure 6A–B). Low-dose simvastatin significantly decreased
avascular areas by 36% when compared to controls (Figure 6C).
High-dose simvastatin significantly increased pathological neovas-
cularisation by 40% (Figure 6D); moreover the neovascular
formations were larger and more confluent in the retinas of
animals on the high dose regime (Figure 6B). Consistent with these
findings, normovascular areas were significantly increased by low-
dose simvastatin treatment, and significantly decreased by the
high-dose treatment (Figure 6E). These data demonstrate that
simvastatin treatment promotes vascular recovery in the ischemic
retina, but only when used at a low dose.
Low Concentration of Simvastatin Induces Akt
Phosphorylation and Stimulates Nitric Oxide Production
Previous results demonstrated an important role for VEGF
mediating low dose-simvastatin effects (Figure 5C–D) and it is also
known that VEGF activates Akt in endothelial cells [20]. In
addition, there is evidence that simvastatin activates the protein
kinase Akt in human umbilical vein endothelial cells (HUVECs)
[16], so the Akt-serine 473 phosphorylation in RMECs treated
with different doses of simvastatin was investigated by Western
blotting. Increased Akt phosphorylation was detected with 0.1 mM
Table 1. Cell Cycle Analysis of RMECs by flow cytometry.
Phase of the Cell Cycle
SubG1 G0/G1 S G2/M
Control 7% 64% 18% 11%
0.1 mM Sim 3% 62% 24% 11%
1 mM Sim 3% 60% 21% 16%
10 mM Sim 13% 64% 13% 10%
10 mM Sim+Mev 5% 64% 16% 15%
Analysis of Cell Cycle was based on DNA content by Propidium Iodide staining
assessed by flow cytometry. The values represent means from a total of 10 000
events per group.
doi:10.1371/journal.pone.0002584.t001
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amount of Akt phosphorylation. No changes in total Akt were
detected with respective simvastatin concentrations.
Because endothelial Nitric Oxide Synthase (eNOS) is known to
be an Akt substrate [21], nitric oxide (NO) production was studied
in RMECs treated with simvastatin. NO production was
significantly increased by 31% in RMECs treated with 0.1 mM
simvastatin when compared to controls (Figure 7B) which is
consistent with Akt activation at the same simvastatin concentra-
tion. Higher concentrations of simvastatin had no significant effect
on NO production. These data provide an insight into possible
mechanisms that explain the pro-vascular repair effects of low
doses of simvastatin in RMECs, such as Akt activation and NO
production.
Figure 2. High-Dose Simvastatin Induces Cell Death on RMECs. (A) Analysis of cell death using PI staining and flow cytometry on RMECs after
24 hour-exposure to simvastatin. The number on the top-right corner of each treatment represents the percentage of dead cells (sub-G1 population).
(B) Immunocytochemistry for TUNEL to identify dead cells after 24 hour- simvastatin treatment. Scale bars 100 mm. (C) Quantification of TUNEL-
positive cells on RMECs exposed to simvastatin. *p,0.05, ***p,0.001 vs. controls; ###p,0.001 vs. 10 mM simvastatin, ns:not significant, n=5 per
group.
doi:10.1371/journal.pone.0002584.g002
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Intracellular Cholesterol and Disorganization of Actin
which Alters Cell Polarisation during Migration
Here, we observed that the effect of high dose simvastatin on
inducing cell death was highly dependent on cholesterol
biosynthesis because mevalonate fully reversed the pro-apoptotic
effects of high-dose simvastatin (Figure 2C), indicating that
intracellular cholesterol metabolism is very important for cell
survival. Therefore we assessed the effect of different doses of
simvastatin on intracellular cholesterol levels using a quantitative
fluorimetric method. 10 mM simvastatin significantly decreased
intracellular cholesterol in RMECs by 47% when compared to
controls (Figure 8). This drastic intracellular cholesterol reduction
corresponds to the cell death induction by 10 mM simvastatin.
Lower simvastatin concentrations also reduced intracellular
cholesterol levels, but to a minor extent, by less than 20%.
Simvastatin can attenuate basal stress fiber formation on
pulmonary artery endothelial cells by reducing phosphorylation
of myosin light chains [22]. Stress fibers are actin filaments whose
formation and remodelling is essential for cell migration, and our
results indicated that 10 mM simvastatin inhibits RMEC migra-
tion. Therefore we addressed the question whether stress fiber
organization in RMECs could be disrupted by simvastatin. RMEC
monolayers showed abundant stress fibers. Although 0.01 mM
simvastatin did not affect stress fiber formation, 10 mM simvastatin
significantly reduced stress fiber formation (Figure 9A). 12 hour-
exposure of 10 mM simvastatin to RMEC monolayers resulted in a
complete disorganization of actin fibers, an effect that can be
reversed by the addition of mevalonate.
To further characterise the effect of simvastatin on RMEC
migration, cellular polarisation of the Golgi apparatus, microtu-
bule organisation centre (MTOC), and caveolin was studied in the
scratch wound assay using immunocytochemical staining. When
RMECs migrated, lamellipodia were formed at the leading edge of
the plasma membrane and the Golgi apparatus and MTOC were
similarly polarised to the aspect of the nucleus facing the leading
edge. The Golgi apparatus identified by the staining of the protein
Golgin 97 was polarised toward the leading edge in 73% of the
Figure 3. Evaluation of Simvastatin Effect on RMEC Migration.
(A) Representative images of the scratch migration wound assay on
RMECs treated with simvastatin. White dotted lines mark the wound
edge at time-0. (B) Quantification of migrated area 12 hours after the
scratch. *p,0.05, **p,0.01 vs. controls; ##p,0.01 vs. 0.01 mM
simvastatin, ns:not significant, n=4 per group.
doi:10.1371/journal.pone.0002584.g003
Figure 4. Biphasic Effect of Simvastatin on RMEC Sprouting. (A)
Representative phase-contrast images of the sprouting assay on RMECs
cultured with 0.01–10 mM simvastatin. White dotted lines represent the
boundary between the primary- and secondary-blobs of Matrigel. White
arrows mark endothelial sprouts invading the secondary-blob that were
quantified for statistical assessment. Note that the shown images are
representative fractions (1/12) of the corresponding Matrigel blob-
whole circumference. (B) Quantification of the number of sprouts per
Matrigel blob. ***p,0.001 vs. controls; #p,0.05 vs. 0.01 mM simvas-
tatin, ns:not significant, n=3 per group.
doi:10.1371/journal.pone.0002584.g004
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showed a polarised Golgi in 74% of migrating cells; however
10 mM simvastatin treatment significantly reduced organelle
polarisation with only 21% of cells presenting a Golgi polarised
towards the wound. Mevalonate could partially reverse this effect
and increased the percentage of RMECs with a polarised Golgi to
Figure 5. Low-Dose Simvastatin Promotes RMEC Tubulogenesis via VEGF. (A) Quantification of tube length per field to measure and
compare tube formation on RMECs exposed to 0.01–10 mM simvastatin. *p,0.05, ***p,0.001, n=4 per group. (B) Representative images of RMECs
cultured on Matrigel and exposed to simvastatin for 3 days. Addition of ranibizumab (Ran) inhibited tube formation on VEGF and 0.01 mM simvastatin
groups. (C) Quantification of tube length to demonstrate that 0.1 mM simvastatin effect inducing tubulogenesis involves VEGF. ***p,0.001 vs.
control; ###p,0.001 vs. no ranibizumab-respective groups, n=6 per group. (D) Quantification of sprout number to demonstrate that 0.1 mM
simvastatin effect inducing sprouting is mediated by VEGF. ***p,0.001, **p,0.01 vs. control; ###p,0.001, ##p,0.01 vs. no ranibizumab-
respective groups, n=3 per group.
doi:10.1371/journal.pone.0002584.g005
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was also examined (Figure 9C): MTOC, defined as the region
from which most microtubules stained with a-tubulin were seen to
arise, was quantified as being polarised when facing the wound
scratch. Resembling previous results for Golgi polarisation, 10 mM
simvastatin significantly decreased the percentage of cells with a
polarised MTOC, and mevalonate could partially reverse this
effect (Table 2). A role for caveolae in cell migration has also been
described [23], so localization of caveolae in the migrating RMEC
was identified by immunocytochemistry for caveolin-1. In contrast
to the Golgi apparatus and the MTOC polarisation at the leading
edge, caveolin-1 was found to accumulate in the rear of most
migrating cells as recently reported [24]. 0.01 mM simvastatin-
treated RMECs showed the same polarisation pattern for
caveolin-1 in the trailing edge, on the contrary there was no
specific polarisation for caveolin-1 when RMECs were treated
with 10 mM simvastatin (Figure 9D) with caveolin-1 evenly
distributed throughout the plasma membrane, both in the leading
and trailing edge of the cells. This effect could also be reversed by
the addition of mevalonate.
These experiments revealed evidence to suggest that high-dose
simvastatin induction of cell death is linked to an acute decrease in
intracellular cholesterol and a complete disorganization of stress
fibers. The same mechanisms may also explain the inhibition of
Figure 6. Low-Dose Simvastatin Promotes Vascular Repair in the Ischaemic Retina. (A) Representative images of P18 flat mounted retinas
from the oxygen-induced retinopathy murine model. Animals were treated with high- and low-doses of simvastatin from P12 to P17. Lectin staining
(green) identifies retinal vasculature, avascular areas are surrounded by yellow lines, and neovascular tufts indicated by red arrows. (B) Higher
magnification of lectin-stained flat mounted retinas to show differences in neovascular formations according to the treatment. (C) Quantificationo f
avascular areas per group. **p,0.01 vs. control; ns, not significant. (D) Quantification of neovascular areas per group. **p,0.01 vs. control; ns, not
significant. (E) Quantification of normovascular areas per group. **p,0.01,*p,0.05 vs. control; ns, not significant. Error bars in C, D, and E denote
standard errors of at least nine independent samples. The statistical significance of differences between controls and simvastatin-treated groups was
determined by one-way ANOVA with Dunnett’s post-test using GraphPad InStat Version 3.06.
doi:10.1371/journal.pone.0002584.g006
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associated with an impairment of the typical cell polarisation of
the Golgi apparatus and MTOC at the leading edge, and caveolin
at the trailing edge.
Discussion
Statins are ubiquitously used throughout the Western world as a
therapeutic strategy to control hypercholesterolaemia [25] and
thus reduce cardiovascular risk [26]. In some instances, these
drugs have been shown to protect against retinopathic progression
in diabetic patients and although this may be linked to correction
of dyslipidaemia [27], which is a known DR risk factor, it remains
possible that statins could directly impact the retinal microvascu-
lature. The current study has evaluated key components of retinal
microvascular pathophysiology, particularly focusing on the
capillary endothelium since these cells are highly sensitive to the
diabetic milieu and are central to DR pathology [28]. Using data
obtained from complementary in vitro and in vivo analysis, we
demonstrate, for the first time, that simvastatin has a clear
pleiotropic effect on the retinal capillary endothelium.
The dose range used in the current investigation has been
carefully chosen to reflect statin use in the clinical situation [29].
However, direct extrapolation of these results to tissue levels
experienced by the retina of patients has not been possible.
Nevertheless, pharmacokinetic studies have previously demon-
strated that serum levels of simvastatin range between 5–30 ng/ml
(0.01–0.07 mM) following a single dose of 40 mg (approximately
0.6 mg/Kg) [30]. It can be assumed that the retinal microvascu-
lature is exposed at least to these concentrations in vivo and it
should be appreciated that simvastatin is prescribed at ‘‘for-life’’
daily doses. Therefore, it seems reasonable to suggest that
therapeutic regimes of high-dose statin could lead to considerably
elevated tissue accumulations of the drug, especially when
considering the lipophilic nature of these compounds.
Previous reports showed that statins have a profound effect on
endothelial cell function [18,31]. Using these studies as a
foundation, we have evaluated the effects of simvastatin on several
aspects of reparative retinal angiogenesis. Our results indicate that
simvastatin has a biphasic dose-related action on RMECs. Low
concentrations were pro-angiogenic with 0.1 mM simvastatin
significantly increasing cell proliferation, and 0.01 mM simvastatin
significantly promoting cell migration, sprouting, and tubulogen-
esis. High concentrations of simvastatin (.5 mM) had the opposite
effect, inhibiting cell proliferation, migration, sprouting and
tubulogenesis. Furthermore it is apparent that simvastatin
concentrations higher than 1 mM are able to induce cell death.
These results indicate that although RMECs are very different to
HUVECs, their biphasic response to simvastatin is similar.
To clearly elucidate simvastatin effect on the retinal vasculature
in vivo, the murine OIR model was used as an appropriate system
to study retinal ischaemia leading to pre-retinal neovascularisation.
Although relatively acute in nature and based on neonates, the
pathology of OIR enables some reasonable comparisons to the
late, ischaemic phase of DR. Our results demonstrate that low
dose of simvastatin (0.2 mg/Kg) promotes vascular repair in the
ischemic retina and this would make it potentially beneficial for
preventing vasodegeneration in the context of DR if introduced at
the appropriate disease time-frame. Interestingly, the high dose of
simvastatin (20 mg/Kg) decreased normal vascularisation, and
increased the pathological neovascularisation when compared to
controls. It is possible that because simvastatin treatment was
started in the hypoxic phase (P12–P15), the high dose actually
retarded vascular recovery and increased the hypoxia which in
turn led to enhanced pathological neovascularisation. The
potential for high-dose statins to abrogate retinal microvascular
repair and thus accelerate vasodegeneration would account for the
observed enhancement of ischaemia-induced neovascularisation.
This conclusion is supported by the complementary in vitro and in
vivo studies.
Our observed pleiotropic effects of statins on endothelial cells
may be linked to multiple, inter-related pathways such as VEGF-
induced cell activation, regulation of eNOS, and also key
signalling responses such as Akt, Rho and Ras [16,32,33]. In the
current investigation, the data indicate that important statin-
Figure 7. Induction of Akt Phosphorylation and Nitric Oxide
Production on RMECs by 0.1 mM Simvastatin. (A) Representative
Western blot reveals the effects of simvastatin on Akt phosphorylation
depended on the dose. Total Akt (tAkt) remained unchanged. (B)
Measurement of nitric oxide production on RMECs exposed to 0.01–
10 mM simvastatin for 24 hours using a NO selective microelectrode.
*p,0.05 vs. controls, ns:not significant, n=3 per group.
doi:10.1371/journal.pone.0002584.g007
Figure 8. Depletion of Intracellular Cholesterol on RMECs by
High-Dose Simvastatin. Determination of intracellular cholesterol
content on RMECs after exposure to 0.01–10 mM simvastatin for
24 hours using the Amplex Red Cholesterol Assay.
***p,0.001,*p,0.05 vs. control; ###p,0.001 vs. 10 mM simvastatin,
ns:not significant, n=4 per group.
doi:10.1371/journal.pone.0002584.g008
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modulated by VEGF and that the statin effects can be significantly
blocked by VEGF neutralisation. Many reports have linked statin
actions on endothelium to VEGF upregulation [34–36], and since
there was no exogeneous VEGF in our in vitro angiogenesis assays,
this could indicate an autocrine effect of low-dose simvastatin on
RMECs. Further linkage to VEGF can be inferred from the
finding that low dose simvastatin induces phosphorylation of Akt
which is a critical pathway in endothelial cell survival and
angiogenesis [37]. Indeed, the Akt pathway is activated by VEGF
[38] and this signalling molecule contributes to endothelial cell
survival, growth, proliferation, and migration [39]. In addition,
Akt phosphorylation activates eNOS [40] which releases NO that,
in turn, stimulates vascular remodelling and angiogenesis. Our
data also show that 0.1 mM simvastatin increases NO production
in RMECs.
High-dose simvastatin appears to have an opposing effect on the
retinal microvascular angiogenic reparative process and signifi-
cantly inhibits cell migration by decreasing intracellular cholesterol
and reducing stress fiber formation. This result is important
because endothelial cell migration and stress fiber formation are
dependent on Rho activation [41] and statins have been shown to
Figure 9. High-Dose Simvastatin Reduces Stress Fiber Formation and Alters RMEC Polarisation during Migration. (A)
Immunocytochemistry for F-actin in green using the FITC-phalloidin probe. Scale bars 100 mm. (B) Labelling of the Golgi apparatus on the leading
edge of migrating RMECs by staning for Golgin 97 in green. Nuclei are stained in red with PI. Scale bars 100 mm. (C) Identification of the MTOC on the
leading edge of migrating RMECs by staning for a-tubulin in green. Nuclei are stained in red with PI. Scale bars 100 mm. (D) Accumulation of caveolin-
1 on the trailing edge of migrating RMECs by immunocytochemistry in green. Nuclei are stained in red with PI. Scale bars 100 mm.
doi:10.1371/journal.pone.0002584.g009
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activation of Rho [42]. It is interesting to note that high-dose
simvastatin causes a significant reduction of intracellular choles-
terol levels in retinal microvascular endothelium. When it is
considered that cholesterol is a key component of cellular
membranes having different roles in cellular viability, cell
migration, lipid raft assembly and cell signalling [43], this high-
dose statin-induced reduction may explain inhibition of cell
migration, sprouting, and healing responses culminating in
premature vascular cell death.
Results from the immunocytochemical analysis of RMEC
polarisation on the scratch wound migration assay (Figure 9 and
Table 2) show a strong correlation between polarisation of the
Golgi apparatus (73%) and the MTOC (77%) at the leading
edge of non-treated RMECs. When treated with 0.01 mM
simvastatin, again the Golgi complex and the MTOC similarly
polarised to the leading edge (74% and 86% respectively),
however 10 mM simvastatin interfered more with the Golgi
polarisation which decreased by 71% when compared to
controls, while the MTOC polarisation only decreased by
38%. This finding is important as it demonstrates that lowering
intracellular cholesterol levels induces an abnormal Golgi
complex polarisation in RMECs. It is well-known that the Golgi
complex play an essential role in cholesterol transport from its
origin in the endoplasmic reticulum to the plasma membrane
[44]; therefore modulating cholesterol levels is more likely to
affect the Golgi than the MTOC.
Our data indicate the existence of two distinct mechanisms of
action for simvastatin on RMECs: the pro-vascular repair
mechanism that involves VEGF stimulation, Akt phosphorylation
and NO production, and the anti-vascular repair mechanism
driven by intracellular cholesterol depletion and actin disorgani-
sation. When simvastatin is used at low doses, the pro-reparative,
angiogenic mechanism promotes vascular integrity. However, at
high doses the cholesterol depletion is limiting, overwhelming any
pro-vascular repair mechanism. This is consistent with the finding
that mevalonate fully reversed cell death-induction by high-dose
simvastatin, while it could, at best, only partially block pro-
angiogenic effects.
In summary, low-dose simvastatin enhances retinal capillary
endothelial cell survival, promotes healing responses and modu-
lates angiogenic repair by reducing ischaemia and thereby
preventing pre-retinal neovascularisation. High-dose simvastatin
prevents reparative function and induces premature death of the
retinal microvascular endothelium, which in vivo, translates into
excessive ischaemia-induced neovascular pathology. We have not
directly evaluated the effects of statins on the diabetic retina but
many of the associated vascular pathologic endpoints have been
investigated. More research is warranted but there is a clear
indication that statin dosage should be judiciously monitored in




Primary RMECs were freshly prepared from bovine eyes
according to standard isolation procedures previously described
[45]. RMECs were cultured on 1% gelatin coated flasks, with
DMEM (PAA Labs GmbH, Pasching, Austria) supplemented with
10% porcine serum (Sigma, Gillenham, UK), 100 mg/ml insulin
(Sigma), 1 mg/ml heparin (Sigma), and 500 mg/ml Primocin
(Autogen Bioclear Ltd, Wiltshire, UK). Passages 3 to 6 were used
for experimentation.
Reagents
Reagents used were: Simvastatin Sodium Salt from Calbiochem
(Merck, Darmstadt, Germany), and N-omega-nitro-L-arginine
methyl ester (L-NAME), Mevalonate, farnesol, and geranylgeranyl
pyrophosphate from Sigma.
Cell Proliferation and Bromodeoxyuridine (BrdU)
Incorporation Assay
When RMECs monolayers were 50% confluent, the total cell
number per flask was assessed using an Improved Neubauer
haemocytometer (Agar Scientific, Essex, UK) and simvastatin
treatments started. After 48 hours, the number of cells per flask was
counted, and the Population Doubling Level (PDL) was calculated.
For monitoring DNA synthesis, cells were pre-treated with
30 mM BrdU (Sigma) for 45 minutes prior to fixation in 99%
ethanol at 220uC for 20 minutes. Microwave treatment in
10 mM Citrate buffer pH 6.0 was used to denature DNA for
antigen retrieval, and cells were stained using monoclonal mouse
anti-BrdU (DAKO UK Ltd, Cambridgeshire, UK) as primary
antibody, and Alexa Fluor 488 goat anti-mouse IgG (Molecular
Probes, Invitrogen Ltd, Paisley, UK) as secondary antibody and
visualised by a fluorescence microscope (Nikon).
Propidium Iodide (PI) Cell Death Assay and TUNEL
Staining
Cell death was analysed 24 hours after simvastatin treatment.
RMECs were harvested and fixed in ice cold 70% ethanol. Cells
were resuspended at 0.5610
6 cells/ml in staining buffer composed
of 100 mg/ml RNase-A (Sigma), and 40 mg/ml PI (Sigma) in PBS,
and incubated at 37uC for 30 minutes. Cells were washed in PBS
twice and analysed using a Flow Cytometer (FACScalibur, BD
Biosciences, Oxford, UK). Dead cells were detected on a PI
histogram as a hypodiploid peak named sub-G1 population. Cell
cycle analysis was performed on the same samples.
DNA fragmentation was visualized by TUNEL technology,
using an In Situ Cell Death Detection Kit (Roche, Burgess Hill,
UK) following manufacturer instructions. Briefly, after microwave
treatment in 0.1 M Citrate buffer pH 6.0, DNA strand breaks
were detected by 39-end labelling with fluorescein-dUTP using a
terminal deoxynucleotidyl transferase.
Table 2. Percentage of cells with polarised morphology.
Control 0.01 mMS i m 1 0mMS i m 1 0mMS i m +Mev
Golgi polarisation 7363% 7468% 2164% *** 4968% ### (n=8)
MTOC polarisation 7762% 8662% 4864% *** 6665% ## (n=3)
Immunocytochemistry for the proteins Golgin 97 and a-tubulin were used to identify the Golgi apparatus and MTOC, respectively. Percentage of endothelial cells with
the Golgi apparatus/MTOC polarised to the leading edge in the Wound Scratch Migration Assay were quantified. All results are presented as mean6SD.
***p,0.001 vs.
Control; ###p,0.001 vs. 10 mM Sim; ##p,0.01 vs. 10 mM Sim.
doi:10.1371/journal.pone.0002584.t002
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RMECs were grown on 1 cm wells previously labelled with
traced lines in order to photograph the same regions. When cells
were 90% confluent, simvastatin treatment was started. After
24 hours, a uniform straight scratch was made in the monolayer
using a 200 ml pipette tip. After injury, cells were gently washed,
the medium was changed, and reference photographs were taken
using a phase contrast microscope Eclipse E400 (Nikon, Japan).
After 12 hours, photographs were again taken and the endothelial
cell migration into the denuded area was quantified by comparing
areas immediately after the scratch with the ones taken 12 hours
later. Lucia software was used to measure areas in mm
2.
Angiogenic Sprouting and Tubulogenesis Assay
An in vitro angiogenic sprouting assay was performed as
previously described [11]. Briefly, 0.5610
6 RMECs were
resuspended in 25 ml DMEM with respective simvastatin treat-
ments, and mixed in a 1:1 ratio with growth factor-reduced
Matrigel (BD Biosciences). 50 ml aliquots were spotted onto 4 well
plates (NUNC, Roskilde, Germany). After Matrigel polymerisa-
tion, blobs were covered in DMEM with 10% porcine serum and
different simvastatin concentrations. 24 hours later, medium was
aspirated and a second layer of Matrigel was superimposed upon
the primary spots creating duplex cultures which were covered
with DMEM containing the respective simvastatin treatments.
36 hours after creating the duplex cultures, endothelial sprouts
could be easily identified invading the secondary gel layer. The
number of endothelial sprouts around the circumference of each
spot was quantified in 6 cultures per treatment.
For the assessment of tube-like structures formation, 24 well-
plates were coated with a basement membrane matrix prepara-
tion: growth factor-reduced Matrigel diluted 1:2 in DMEM.
RMECs were plated at a density of 10
4 cells/well and incubated in
0.01–10 mM simvastatin at 37uC for 3 days. 50 ng/ml VEGF
(R&D Systems, Abingdon, UK) was used as a positive control. To
test whether simvastatin effects involved VEGF signalling, a
VEGF neutralising Fab fragment ranibizumab (Novartis, Basel,
Switzerland) was used at a 1/50 dilution (200 mg/ml). Images
were captured using a phase contrast microscope Eclipse E400
(Nikon).
Immunocytochemistry
RMECs were fixed in 4% paraformaldehyde for 30 minutes at
room temperature. After blocking with 5% goat serum in PBS
with 0.1% Tween 20 for one hour at room temperature, cells were
treated with a primary antibody overnight at 4uC. After washing
with PBS, cells were incubated with appropriate secondary
antibodies for one hour at room temperature, and observed on a
Confocal Fluorescence Scanning Microscope (Olympus BX60
epifluorescence microscope fitted with a BioRad Microradiance
Confocal imaging system equipped with argon-ion and green
Helium-Neon lasers). Omission of the first antibodies consistently
gave no signals confirming absence of non-specific binding of
secondary antibodies. The primary antibodies used were anti-
bovine a-tubulin (Molecular Probes), anti-golgin-97 (Molecular
Probes) and caveolin-1 (BD Biosciences). Respective anti-rabbit
and anti-mouse Alexa Fluor 488 IgGs were used as secondary
antibodies. For labelling F-actin, the FITC-phalloidin probe
(Molecular Probes) was used.
Oxygen-Induced Retinopathy Model
All experiments were performed in conformity to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research, and UK Home Office Regulations. Oxygen-Induced
Retinopathy (OIR) was induced in C57/Bl6 wild type mice
according to the protocol of Smith et al [46]. Briefly, P7 newborn
mice and their nursing dams were exposed to 75% oxygen (Pro-
Ox 110 Chamber Controller Used, Biospherix, Redfield, NY,
USA) for 5 days. At P12, they were transferred back to room air
cages. Hyperoxia exposure produces widespread vaso-obliteration
in the central retinal capillary beds with profound ischaemic
hypoxia upon return to room air. Around P15 the retinal
ischaemia initiates an aggressive neovascular response at the
interface of the perfused retinal periphery and the ischaemic
central capillary beds. The neovascularisation is maximal at P17
and declines thereafter. 22 mice were divided into four groups:
Group 1 with four pups as P12 controls to check the central vaso-
obliteration following hyperoxia; Groups 2, 3, and 4 contained six
pups each; Group 2 received daily intraperitoneal injections of a
high dose of simvastatin (20 mg/g/day) for 6 days from P12 to
P17; Group 3 received a low dose of simvastatin (0.2 mg/g/day)
and Group 4 received no treatment. All intraperitoneal injection
volumes were adjusted to 40–50 ml. Pups from groups 2, 3, and 4
were killed at P18 with sodium pentobarbital; the eyes were
enucleated and fixed in 4% paraformaldehyde. Retinal flat mounts
were stained with isolectin B4 (Sigma) and Streptavidin Alexa
Fluor 488 (Molecular Probes). Stained retinas were visualised and
imaged using a fluorescence microscope and digital camera (Nikon
Eclipse). Avascular, neovascularised, and normally vascularised
retinal areas were quantified using Image J software.
Intracellular Cholesterol Quantification
To measure the intracellular cholesterol content of RMECs, the
Amplex Red Cholesterol Assay Kit (Molecular Probes) was used.
After 24 hours exposure to different concentrations of simvastatin,
RMECs were harvested, counted and 1 million cells per group
were lysed in RIPA lysis buffer for later reaction with the Amplex
Red Reagent according to the manufacturer’s protocol. Fluores-
cence was measured by a Safire Microplate Reader (Tecan,
Reading, UK) using excitation at 530 nm and emission detection
at 590 nm.
Western Blotting
Proteins from simvastatin treated-RMECs and controls were
precipitated with 10% trichloroacetic acid, and dissolved in 9 M
urea (Sigma), 2 M thiourea (Sigma) and 4% CHAPS (Melford
Laboratories,Suffolk, UK). 20 mg of protein were loaded per lane
and separated with Tris-HEPES-SDS polyacrylamide gels,
transferred to a PVDF membrane, and blocked with 5% Blotto
(Santa Cruz Biotechnology, CA) in Tris Buffered Saline with 0.1%
Tween-20 (TBST). Total and phosphorylated Akt (Ser 473) were
detected with polyclonal antibodies from Cell Signaling Technol-
ogy (Danvers, MA). After washing with TBST, respective
horseradish peroxidase-conjugated secondary antibodies (Santa
Cruz Biotechnology) were applied, and the blots were developed
using the AutoChemi chemilumininescence imaging system (UVP,
Upland, CA). PVDF membranes were re-probed with a
monoclonal antibody to GAPDH (IMGENEX, San Diego, CA)
as a loading control.
Electrochemical Detection of Nitric Oxide (NO)
Production
Medium from 24 hour simvastatin-treated RMECs was collect-
ed and stored at 220uC. NO release was measured using a NO
selective microelectrode (ami NO-700, Innovative Instruments
Inc, Tampa, FL) and an amplifier inNO meter (Innovative
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H2SO4 solution with 0.5% KI converted the nitrite in the medium
to NO, which was measured using the microelectrode that had
been previously calibrated using sodium nitrite standards (250 nM
to 3000 nM). NO production was measured as pmol/ml.
Statistical Analysis
All data are expressed as mean6SEM unless otherwise stated.
Statistical significance was evaluated by one-way ANOVA with
Dunnett’s / Tukey-Kramer’s post-test using GraphPad InStat
version 3.06 for Windows, GraphPad Software, San Diego,
California, USA.
Acknowledgments
We thank Pauline Linton for her constant support isolating RMECs from
bovine retinas, and Dr Julia Busik for her expert advice for measuring
intracellular cholesterol levels.
Author Contributions
Conceived and designed the experiments: AS RM TG. Performed the
experiments: RM CO. Analyzed the data: AS RM CO TG. Wrote the
paper: AS RM. Other: Performed nitric oxide measurements: AD.
References
1. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary
heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:
1383–1389.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. (1995) Prevention
of coronary heart disease with pravastatin in men with hypercholesterolemia.
West of Scotland Coronary Prevention Study Group. N Engl J Med 333:
1301–1307.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The
effect of pravastatin on coronary events after myocardial infarction in patients
with average cholesterol levels. Cholesterol and Recurrent Events Trial
investigators. N Engl J Med 335: 1001–1009.
4. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with
simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled
trial. Lancet 360: 7–22.
5. Bonetti PO, Lerman LO, Napoli C, Lerman A (2003) Statin effects beyond lipid
lowering–are they clinically relevant? Eur Heart J 24: 225–248.
6. NIH (2006) Statins for the prevention of cardiovascular events: Technology
Appraisal Guidance 94. London, .
7. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. (2008) Efficacy of
cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised
trials of statins: a meta-analysis. Lancet 371: 117–125.
8. Cheung BM (2008) Statins for people with diabetes. Lancet 371: 94–95.
9. Watkins PJ (2003) Retinopathy. Bmj 326: 924–926.
10. Mizutani M, Kern TS, Lorenzi M (1996) Accelerated death of retinal
microvascular cells in human and experimental diabetic retinopathy. J Clin
Invest 97: 2883–2890.
11. Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, et al.
(2005) Impaired retinal angiogenesis in diabetes: role of advanced glycation end
products and galectin-3. Diabetes 54: 785–794.
12. Frank RN (2004) Diabetic retinopathy. N Engl J Med 350: 48–58.
13. Tawfik HE, El-Remessy AB, Matragoon S, Ma G, Caldwell RB, et al. (2006)
Simvastatin improves diabetes-induced coronary endothelial dysfunction.
J Pharmacol Exp Ther 319: 386–395.
14. Sen K, Misra A, Kumar A, Pandey RM (2002) Simvastatin retards progression
of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin
Pract 56: 1–11.
15. Zhang J, McGwin G Jr (2007) Association of statin use with the risk of
developing diabetic retinopathy. Arch Ophthalmol 125: 1096–1099.
16. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, et al. (2000) The HMG-CoA
reductase inhibitor simvastatin activates the protein kinase Akt and promotes
angiogenesis in normocholesterolemic animals. Nat Med 6: 1004–1010.
17. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, et al. (2002) 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by
inhibiting the geranylgeranylation of RhoA. Circ Res 91: 143–150.
18. Urbich C, Dernbach E, Zeiher AM, Dimmeler S (2002) Double-edged role of
statins in angiogenesis signaling. Circ Res 90: 737–744.
19. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, et al. (2001) Hsp90
and caveolin are key targets for the proangiogenic nitric oxide-mediated effects
of statins. Circ Res 89: 866–873.
20. Fujio Y, Walsh K (1999) Akt mediates cytoprotection of endothelial cells by
vascular endothelial growth factor in an anchorage-dependent manner. J Biol
Chem 274: 16349–16354.
21. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, et al. (1999)
Activation of nitric oxide synthase in endothelial cells by Akt-dependent
phosphorylation. Nature 399: 601–605.
22. Jacobson JR, Dudek SM, Birukov KG, Ye SQ, Grigoryev DN, et al. (2004)
Cytoskeletal activation and altered gene expression in endothelial barrier
regulation by simvastatin. Am J Respir Cell Mol Biol 30: 662–670.
23. Navarro A, Anand-Apte B, Parat MO (2004) A role for caveolae in cell
migration. Faseb J 18: 1801–1811.
24. Parat MO, Anand-Apte B, Fox PL (2003) Differential caveolin-1 polarization in
endothelial cells during migration in two and three dimensions. Mol Biol Cell 14:
3156–3168.
25. Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA
reductase inhibitors. Nat Rev Drug Discov 2: 517–526.
26. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK (2006) Primary
prevention of cardiovascular diseases with statin therapy: a meta-analysis of
randomized controlled trials. Arch Intern Med 166: 2307–2313.
27. Gordon B, Chang S, Kavanagh M, Berrocal M, Yannuzzi L, et al. (1991) The
effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 112:
385–391.
28. Badr GA, Tang J, Ismail-Beigi F, Kern TS (2000) Diabetes downregulates
GLUT1 expression in the retina and its microvessels but not in the cerebral
cortex or its microvessels. Diabetes 49: 1016–1021.
29. Moon JC, Bogle RG (2006) Switching statins. Bmj 332: 1344–1345.
30. Lilja JJ, Neuvonen M, Neuvonen PJ (2004) Effects of regular consumption of
grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 58:
56–60.
31. Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic
effects on angiogenesis. Circulation 105: 739–745.
32. Rikitake Y, Liao JK (2005) Rho GTPases, statins, and nitric oxide. Circ Res 97:
1232–1235.
33. Ii M, Losordo DW (2007) Statins and the endothelium. Vascul Pharmacol 46:
1–9.
34. Chen SD, Hu CJ, Yang DI, Nassief A, Chen H, et al. (2005) Pravastatin
attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells
with HIF-1 activation and VEGF upregulation. Ann N Y Acad Sci 1042:
357–364.
35. Matsuno H, Takei M, Hayashi H, Nakajima K, Ishisaki A, et al. (2004)
Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in
injured arteries. J Cardiovasc Pharmacol 43: 333–340.
36. Frick M, Dulak J, Cisowski J, Jozkowicz A, Zwick R, et al. (2003) Statins
differentially regulate vascular endothelial growth factor synthesis in endothelial
and vascular smooth muscle cells. Atherosclerosis 170: 229–236.
37. Shiojima I, Walsh K (2002) Role of Akt signaling in vascular homeostasis and
angiogenesis. Circ Res 90: 1243–1250.
38. Morales-Ruiz M, Fulton D, Sowa G, Languino LR, Fujio Y, et al. (2000)
Vascular endothelial growth factor-stimulated actin reorganization and
migration of endothelial cells is regulated via the serine/threonine kinase Akt.
Circ Res 86: 892–896.
39. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream.
Cell 129: 1261–1274.
40. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, et al. (1999) Regulation
of endothelium-derived nitric oxide production by the protein kinase Akt.
Nature 399: 597–601.
41. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW
(2003) Involvement of RhoA/Rho kinase signaling in VEGF-induced endothe-
lial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol 23:
211–217.
42. Wolfrum S, Jensen KS, Liao JK (2003) Endothelium-dependent effects of statins.
Arterioscler Thromb Vasc Biol 23: 729–736.
43. Boukhtouche F, Mariani J, Tedgui A (2004) The ‘‘CholesteROR’’ protective
pathway in the vascular system. Arterioscler Thromb Vasc Biol 24: 637–643.
44. Ikonen E (2006) Mechanisms for cellular cholesterol transport: defects and
human disease. Physiol Rev 86: 1237–1261.
45. Coleman G, Gardiner TA, Boutaud A, Stitt AW (2007) Recombinant
alpha2(IV)NC1 domain of type IV collagen is an effective regulator of retinal
capillary endothelial cell proliferation and inhibits pre-retinal neovascularisation.
Graefes Arch Clin Exp Ophthalmol 245: 581–587.
46. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D’Amato R, et al. (1994)
Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:
101–111.
Statins in Retinal Ischaemia
PLoS ONE | www.plosone.org 12 July 2008 | Volume 3 | Issue 7 | e2584